News
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback